SGEN Company Profile and Key Details

Q: Who are the executives of SGEN?

Mr. Todd E. SimpsonChief Financial OfficerMr. David CaouetteVice President of Corporation CommunicationsMs. Peggy M. PinkstonChief HR OfficerPeggy PinkstonSenior Vice President of Investor RelationsMr. Charles R. RompExecutive Vice President of Commercial U.S.Dr. Roger D. Dansey M.D.Chief Medical Officer and Pres of R&DMr. Matt SkeltonVice President of MarketingMs. Jean I. Liu J.D., M.S.Chief Legal Officer & Corporation Sec.Dr. Vaughn B. Himes Ph.D.Chief Technical OfficerMr. Christopher P. PawlowiczExecutive Vice President of HRMs. Peggy PinkstonChief HR OfficerMr. William ComptonChief Information Officer & Corporation Vice PresidentMr. David R. Epstein B.Sc., M.B.A.Consultant

NASDAQ : SGEN

Seagen

$228.74

-0.16-0.07%

At Close 4:00 PM

Not Actively Trading

52.22

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Seagen Inc. (SGEN) stock declined over -0.07%, trading at $228.74 on NASDAQ, down from the previous close of $228.90. The stock opened at $228.93, fluctuating between $228.74 and $228.96 in the recent session.

Stock Snapshot

228.9

Prev. Close

43.15B

Market Cap

228.74

Day Low

-57.185

P/E Ratio

-4

EPS (TTM)

-3.73

Cash Flow per Share

228.93

Open

188.66M

Number of Shares

228.96

Day High

68.82%

Free Float in %

13.56

Book Value

19.39M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2023	228.74	228.74	228.74	228.74	0
Dec 21, 2023	228.74	228.74	228.74	228.74	0
Dec 20, 2023	228.74	228.74	228.74	228.74	0
Dec 19, 2023	228.74	228.74	228.74	228.74	0
Dec 18, 2023	228.74	228.74	228.74	228.74	0
Dec 15, 2023	228.74	228.74	228.74	228.74	0
Dec 14, 2023	228.74	228.74	228.74	228.74	0
Dec 13, 2023	228.93	228.96	228.74	228.74	20.08M
Dec 12, 2023	228.86	228.94	228.81	228.90	12.26M
Dec 11, 2023	220.00	221.72	219.00	221.60	2.12M
Dec 08, 2023	219.00	219.76	218.18	218.98	1.18M
Dec 07, 2023	216.00	219.43	215.93	218.33	2M
Dec 06, 2023	216.11	216.42	215.28	215.80	698.61K
Dec 05, 2023	212.85	215.95	212.67	215.83	1.42M
Dec 04, 2023	212.72	213.25	212.53	213.13	769.65K
Dec 01, 2023	213.60	213.97	212.44	212.72	1.3M
Nov 30, 2023	213.60	213.95	212.82	213.21	1.4M
Nov 29, 2023	214.33	214.65	213.50	213.52	742.97K
Nov 28, 2023	214.42	214.69	213.84	214.16	873.89K
Nov 27, 2023	214.50	214.96	214.05	214.42	767.86K

Contact Details

Bothell, WA 98021

United States

https://www.seagen.com 425 527 4000

About Company

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.43-1.09%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 CDTX

Cidara Therapeutics, Inc.$221.38

Company Overview

Seagen Inc. (NASDAQ:SGEN) closed at $228.74 USD, losing -$0.16 (-0.07%) from the previous close of $228.90. The stock is currently trading near its 52-week high $126.47 and $228.96. With a market capitalization of about $43.15 billion, Seagen Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.32). Key stats such as the average daily volume over the past year has been around 1.63 million shares, trading with heavier-than-usual volume. Headquartered in Bothell, WA, Seagen Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David R. Epstein, the company employs approximately 3,256 people and listed since March 09, 2001. Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

Valuation Metrics

Seagen Inc. trades at a P/E ratio of -69.22, slightly below the S&P 500 average, with a price-to-sales ratio of 21.99 and a price-to-book ratio of 15.07 reflecting a rich premium to book value. The P/FCF stands at -81.26, also below market averages. Compared to sector medians, Seagen Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Seagen Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $126.43. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Seagen Inc. generated EPS of -$4.01 over the past year. Five-year average earnings growth is -30.39%. The latest quarter delivered EPS of -$1.15. The next quarter is forecast at -$1.01. Next year's EPS is expected at $59.65. Seagen Inc. earnings surprise history is a mixed track record. The quarter that ended November 01, 2023, missed forecasts by 61.97%. The prior quarter beat by 44.87%. Over the last six quarters, Apple has recorded several small beats. These include -10.98% in July 28, 2022.

Financial & Profitability Overview

Over the trailing twelve months, Seagen generated $1.96B in revenue, or $10.63 per share. Gross margin was 79.10%, operating margin -31.24%, and net profit margin -31.10%. Returns are negative, with ROA at -16.61% and ROE at -21.77%.
On valuation metrics, Seagen trades at a P/E of -69.22, P/S of 21.99 and P/B of 15.07. The current ratio is 2.12 and quick ratio is 1.60. Operationally, the company’s inventory turnover is 0.96 and cash conversion cycle is 288.61 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -10.44.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Seagen posted revenue of $1.96B, down slightly from $1.57B in the prior quarter. Gross profit was $1.55B (margin 79.10%). Operating income was - $612.97M (margin -31.2%). Net income was- $610.31M (EPS - $3.30).
The company ended the quarter with $1.74B in cash and short-term investments, a total debt of $43.47M, and net debt of - $276.47M. Total assets were $3.67B, with equity of $2.80B. Financials further reflected weakness, with operating cash flow of - $453.75M, free cash flow of - $531.09M, and capital expenditures of - $77.34M.

Price Forecast & Outlook

Our AI price prediction model suggests that Seagen Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.25%, with price expected at $247.61 by January 05, 2024, within a range of $245.28 to $250.23 1-Year Outlook: Projected gain of 149.12%, with price at $569.84 by December 20, 2024, within a range of $557.84 to $581.71.

Key Takeaways

Valuation shows Seagen Inc. trading at a premium to the broader market with a P/E of -69.22. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $179.97, suggesting -21.32% downside.

Frequently Asked Questions

What is the current Seagen Inc. (SGEN) stock price?

Seagen Inc. (NASDAQ: SGEN) stock price is $228.74 in the last trading session. During the trading session, SGEN stock reached the peak price of $228.96 while $228.74 was the lowest point it dropped to. The percentage change in SGEN stock occurred in the recent session was -0.07% while the dollar amount for the price change in SGEN stock was - $0.16.

SGEN's industry and sector of operation?

The NASDAQ listed SGEN is part of Biotechnology industry that operates in the broader Healthcare sector. Seagen Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SGEN?

Mr. Todd E. Simpson
Chief Financial Officer
Mr. David Caouette
Vice President of Corporation Communications
Ms. Peggy M. Pinkston
Chief HR Officer
Peggy Pinkston
Senior Vice President of Investor Relations
Mr. Charles R. Romp
Executive Vice President of Commercial U.S.
Dr. Roger D. Dansey M.D.
Chief Medical Officer and Pres of R&D
Mr. Matt Skelton
Vice President of Marketing
Ms. Jean I. Liu J.D., M.S.
Chief Legal Officer & Corporation Sec.
Dr. Vaughn B. Himes Ph.D.
Chief Technical Officer
Mr. Christopher P. Pawlowicz
Executive Vice President of HR
Ms. Peggy Pinkston
Chief HR Officer
Mr. William Compton
Chief Information Officer & Corporation Vice President
Mr. David R. Epstein B.Sc., M.B.A.
Consultant

How SGEN did perform over past 52-week?

SGEN's closing price is 80.86% higher than its 52-week low of $126.47 where as its distance from 52-week high of $228.96 is -0.1%.

How many employees does SGEN have?

Number of SGEN employees currently stands at 3,256.

Link for SGEN official website?

Official Website of SGEN is: https://www.seagen.com

How do I contact SGEN?

SGEN could be contacted at phone 425 527 4000 and can also be accessed through its website. SGEN operates from 21823 30th Drive SE, Bothell, WA 98021, United States.

How many shares of SGEN are traded daily?

SGEN stock volume for the day was 19.39M shares. The average number of SGEN shares traded daily for last 3 months was 1.63M.

What is the market cap of SGEN currently?

The market value of SGEN currently stands at $43.15B with its latest stock price at $228.74 and 188.66M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	3256
Beta	0.32
Sales or Revenue	$1.96B
5Y Sales Change%	2%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SGEN Company Profile and Key Details

Seagen

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics